Retinal vein occlusion

Faricimab

Faricimab, a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor, is approved in the US and Europe to treat wet age-related macular degeneration and diabetic macular oedema. Two phase 3 trials have demonstrated early and sustained vision improvement with faricimab in patients with retinal vein occlusion.[99]ClinicalTrials.gov. A study to evaluate the efficacy and safety of faricimab in participants with macular edema secondary to branch retinal vein occlusion (BALATON).​ ClinicalTrials.gov ID: NCT04740905. Jul 2023 [internet publication]. https://clinicaltrials.gov/study/NCT04740905 [100]ClinicalTrials.gov. A study to evaluate the efficacy and safety of faricimab in participants with macular edema secondary to central retinal or hemiretinal vein occlusion (COMINO).​ ClinicalTrials.gov ID: NCT04740931. Aug 2023 [internet publication]. https://clinicaltrials.gov/study/NCT04740931 ​​ The visual and anatomical outcomes were non-inferior at 24 weeks compared with aflibercept. A large percentage of subjects from the phase 3 trials were able to achieve dosing intervals greater than 4 weeks in each of these conditions. Faricimab also maintained vision improvements with extended treatment intervals up to 4 months.[99]ClinicalTrials.gov. A study to evaluate the efficacy and safety of faricimab in participants with macular edema secondary to branch retinal vein occlusion (BALATON).​ ClinicalTrials.gov ID: NCT04740905. Jul 2023 [internet publication]. https://clinicaltrials.gov/study/NCT04740905 ​[100]ClinicalTrials.gov. A study to evaluate the efficacy and safety of faricimab in participants with macular edema secondary to central retinal or hemiretinal vein occlusion (COMINO).​ ClinicalTrials.gov ID: NCT04740931. Aug 2023 [internet publication]. https://clinicaltrials.gov/study/NCT04740931 ​